Literature DB >> 26109401

Comments on Kagan et al.: Preemptive enteral nutrition enriched with eicosapentaenoic acid, gamma-linolenic acid and antioxidants in severe multiple trauma: a prospective, randomized, double-blind study.

Christopher Uhlig1, Thomas Felbinger, Axel R Heller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26109401     DOI: 10.1007/s00134-015-3926-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  4 in total

1.  Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock.

Authors:  Alessandro Pontes-Arruda; Afra Maria Albuquerque Aragão; Juliana Deusdará Albuquerque
Journal:  Crit Care Med       Date:  2006-09       Impact factor: 7.598

2.  Preemptive enteral nutrition enriched with eicosapentaenoic acid, gamma-linolenic acid and antioxidants in severe multiple trauma: a prospective, randomized, double-blind study.

Authors:  Ilya Kagan; Jonathan Cohen; Michael Stein; Itai Bendavid; Dana Pinsker; Veronica Silva; Miriam Theilla; Ronit Anbar; Shaul Lev; Milana Grinev; Pierre Singer
Journal:  Intensive Care Med       Date:  2015-02-12       Impact factor: 17.440

3.  Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial.

Authors:  R H Bower; F B Cerra; B Bershadsky; J J Licari; D B Hoyt; G L Jensen; C T Van Buren; M M Rothkopf; J M Daly; B R Adelsberg
Journal:  Crit Care Med       Date:  1995-03       Impact factor: 7.598

4.  The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data.

Authors:  Alessandro Pontes-Arruda; Stephen Demichele; Anand Seth; Pierre Singer
Journal:  JPEN J Parenter Enteral Nutr       Date:  2008 Nov-Dec       Impact factor: 4.016

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.